secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001549595-24-000130
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M
--------------------------------------------------------------------------------

- Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.
- Collaboration revenue $12.6M, down from $18.5M, reflecting end of Gilead research term offset by Pfizer deal.
- Cash and marketable securities $457.5M as of Aug 31, 2024, up from $452.5M at May 31, 2024.
- NX-5948 Phase 1b expansion started in CLL, Waldenstrom's, follicular, marginal zone lymphoma; FDA Fast Track for CLL.
- NX-2127 enrollment reinitiated with new chirally controlled drug product after FDA partial clinical hold lift.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000130/0001549595-24-000130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000130/nrix-20241011.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer